You are here
Integrated Biotherapeutics, Inc.
UEI: XNTHMSN2JJP5
# of Employees: 30
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of a Universal Immunotherapeutic for Influenza Viruses
Amount: $1,535,553.00Project Summary Influenza virus (INFV) results in global seasonal and pandemic outbreaks estimated to cause severe illness in 3 to 5 million people annually resulting in significant morbidity and up t ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Immunotherapy of MRSA Osteomyelitis
Amount: $2,000,000.00Methicillin-resistant Staphylococcus aureus (MRSA) causes invasive infections in about 80,000 Americans every year with a 14% overall mortality rate, despite the availability of drugs that are active ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses
Amount: $591,784.00Project Summary Filoviruses, including the Ebola viruses, Marburg viruses, and Cueva virus, are a class of pathogens with enormous health implications. Filoviruses have been implicated in numerous out ...
STTRPhase I2020Department of Health and Human Services National Institutes of Health -
Mining natively paired macque antibodies for Marburg virus protective antibodies
Amount: $600,000.00Project summary Filoviruses are among the deadliest known human viruses. The family Filoviridae contains two clinically relevant genera; Ebolavirus and Marburgvirus that each consist of multiple virus ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Development of a Universal Immunotherapeutic for Influenza Viruses
Amount: $290,038.00Project Summary Influenza virusINFVresults in global seasonal and pandemic outbreaks estimated to cause severe illness intomillion people annually resulting in significant morbidity and up todeathsThe ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
ISTAb- A novel therapy to target staphylococcal toxins at the site of infections
Amount: $600,000.00Project Summary Many bacterial pathogens secrete exotoxins to modify the host-pathogen interactions in a manner that benefits the bacteria. There are several examples of successful prophylaxis and tre ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
Amount: $600,000.00Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as hi ...
STTRPhase I2019Department of Health and Human Services National Institutes of Health -
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
Amount: $2,963,566.00Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can b ...
STTRPhase II2019Department of Health and Human Services National Institutes of Health -
Remodeled glycoprotein for broad protection against ebolaviruses
Amount: $601,655.00Project summary TheEbola virus diseaseEVDoutbreak in West Africacaused by the Zaire Ebola virusEBOVresulted in overcases anddeathsThis has been a sobering reminder of the growing threat of the filovir ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Serotype independent therapeutic vaccine for Streptococcus pneumoniae
Amount: $438,765.00In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health
